320 related articles for article (PubMed ID: 25475885)
1. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
[TBL] [Abstract][Full Text] [Related]
2. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
Okubo M; Morita S; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):93-102. PubMed ID: 26856541
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
[TBL] [Abstract][Full Text] [Related]
4. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.
Kirchheiner J; Henckel HB; Meineke I; Roots I; Brockmöller J
J Clin Psychopharmacol; 2004 Dec; 24(6):647-52. PubMed ID: 15538128
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4.
Störmer E; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1168-75. PubMed ID: 10997935
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
9. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
10. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3.
Okubo M; Narita M; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):83-92. PubMed ID: 26856397
[TBL] [Abstract][Full Text] [Related]
11. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
12. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
13. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
14. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.
Yasui-Furukori N; Hidestrand M; Spina E; Facciolá G; Scordo MG; Tybring G
Drug Metab Dispos; 2001 Oct; 29(10):1263-8. PubMed ID: 11560868
[TBL] [Abstract][Full Text] [Related]
15. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.
Borobia AM; Novalbos J; Guerra-López P; López-Rodríguez R; Tabares B; Rodríguez V; Abad-Santos F; Carcas AJ
Pharmacol Res; 2009 Jun; 59(6):393-8. PubMed ID: 19429471
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator.
Jornil J; Jensen KG; Larsen F; Linnet K
Drug Metab Dispos; 2010 Mar; 38(3):376-85. PubMed ID: 20007670
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model.
Jamshidfar S; Ardakani YH; Lavasani H; Rouini M
Daru; 2017 Jun; 25(1):16. PubMed ID: 28659160
[TBL] [Abstract][Full Text] [Related]
19. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects.
Brockmöller J; Meineke I; Kirchheiner J
Clin Pharmacol Ther; 2007 May; 81(5):699-707. PubMed ID: 17329996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
